Showing results (11-20 of 16,106) with videos related to
Sort By:
Pageof 1,611
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|January 5, 2002
Presence of a pet dog and human cardiovascular responses to mild mental stressB A Kingwell, A Lomdahl, W P AndersonClinical Pharmacology in Drug Development|May 10, 2025
A 2-Part, Open-Label, Phase 1 Bioequivalence and Food-Effect Study of Ubrogepant in Healthy Adult ParticipantsRamesh Boinpally, Joel M TrugmanThe Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 1, 1987
Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesionsJ M Trugman, G F WootenBrain Research|April 2, 1993
D1 dopamine agonist and antagonist effects on regional cerebral glucose utilization in rats with intact dopaminergic innervationJ M Trugman, C L JamesClinical and Translational Science|January 24, 2024
Ubrogepant: Mechanism of action, clinical and translational scienceRamesh Boinpally, Mohamad Shebley, Joel TrugmanNeuropharmacology|June 1, 1989
The dopamine agonist, PHNO ((+)-4-propyl-9-hydroxynaphthoxazine), inhibits cyclic adenosine 3',5'-monophosphate formation and prolactin release from anterior pituitary cellsI S Login, J M TrugmanPhysical Review Letters|December 17, 2004
Exact ground states of a frustrated 2D magnet: deconfined fractional excitations at a first-order quantum phase transitionC D Batista, S A TrugmanThe Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 1, 1992
Rapid development of dopaminergic supersensitivity in reserpine-treated rats demonstrated with 14C-2-deoxyglucose autoradiographyJ M Trugman, C L JamesClinical Pharmacology in Drug Development|July 12, 2024
Effect of a High-Fat Meal on the Pharmacokinetics of an Immediate Release Atogepant TabletRamesh R Boinpally, Joel M TrugmanPageof 1,611